- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05734898
NKG2D CAR-NK & r/rAML
March 1, 2023 updated by: He Huang, Zhejiang University
NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
This trial will explore the maximum tolerated dose(MTD)of NKG2D CAR-NK cells in the treatment of relapsed or/and refractory AML in a dose-escalation manner, and observe the clinical safety and efficacy.
Study Overview
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Hu YongXian
- Phone Number: +86-0571-87236476
- Email: huyongxian2000@aliyun.com
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310003
- Recruiting
- The first affiliated hospital of medical college of zhejiang university
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 years to 75 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: ≥ 3 years old and ≤ 75 years old, male or female;
- Meet the diagnostic criteria for recurrent AML specified in the guidelines for diagnosis and treatment of acute myelogenous leukemia (relapse/refractory) in China (2017): leukemic cells reappear in peripheral blood or bone marrow MRD > 0.1% after complete remission (CR), including relapse after allogeneic hematopoietic stem cell transplantation or extramedullary leukemic cell infiltration.
- Meet the diagnostic criteria for refractory AML specified in the guidelines for diagnosis and treatment of acute myelogenous leukemia (relapse/refractory) in China (2017): Initial cases with failure of 2 lines of standard treatment; patients who relapsed within 12 months after consolidation intensification after CR; recurrence in 12 months and no respond to conventional chemotherapy; 2 or more recurrences; persistent extramedullarial leukemia;
- Patients currently have no effective treatment options, such as chemotherapy or allogeneic hematopoietic stem cell transplantation, or patients voluntarily choose to infuse NKG2D CAR-NK cells as the first treatment option;
- Physical status assessment (ECOG-PS) of the Eastern Oncology Collaborative Group is 0-2 points;
- Life expectancy ≥ 12 weeks from the time of enrollment;
- The main organs of the patient are well functioned: (1) cardiac function: no heart disease or coronary heart disease, the patient's cardiac function grade 1-2; (2) liver function: TBIL≦3ULN, AST≦2.5ULN, ALT≦2.5ULN; (3) Renal function: Cr≦1.25ULN;
- Flow cytometry check for NKG2D ligand expression on the surface of cancer cells as a reference for patient selection;
- The patient's peripheral superficial vein is accessible for IV insertion and blood draws;
- No other serious diseases that conflict with this protocol (e.g., autoimmune diseases, immunodeficiency, organ transplantation);
- No history of other malignant tumors;12. Women of childbearing age must be tested negative for pregnancy within 7 days, and subjects of childbearing age must use appropriate contraception during both the trial and for 3 months after the test;
13. Subjects have negative HIV, HBV, HCV, syphilis serology test results; 14. Written informed consent form must be signed by the patient or the patient's immediate family members before enrollment.
Exclusion Criteria:
- Acute promyelocytic leukemia (Type M3);
- Patients with cardiac insufficiency, patients with liver and renal insufficiency;
- Patients with other malignant tumors need to be treated;
- Poorly controlled hypertension (systolic blood pressure >160 mmHg and/or diastolic blood pressure >90 mmHg) or clinically significant cardiovascular and cerebrovascular diseases such as cerebrovascular accident (within 6 months before signing the informed consent form), myocardial infarction (within 6 months before signing the informed consent), unstable angina, congestive heart failure, or severe arrhythmias that cannot be controlled with drugs or have a potential impact on research treatment;
- Patients suffering from other hematologic diseases (such as hemophilia, myelofibrosis, etc., which researchers consider unsuitable for enrollment);
- Patients with diffuse vascular internal coagulation;
- Patients with concomitant serious infection or other serious underlying medical condition;
- Patients with variable immunodeficiency and autoimmune diseases;
- Patients who have severe allergic diseases;
- Clinical symptoms of brain dysfunction or severe mental illness that can not understand or follow the research protocol;
- Have participated in clinical trials of other drugs within 4 weeks or within 21 days of surgery;
- Have received cell therapy in the previous 1 month;
- Have received hormonal drug therapy in the previous 14 days;
- Known human immunodeficiency virus (HIV) seropositivity or active hepatitis B or C infection or syphilis;
- Have received organ transplants (excluding stem cell transplant patients);
- Drug abuse, medical, psychological or social conditions that may interfere with a subject's participation in the study or evaluation of the results of the study;
- Pregnant or lactating women;
- Those who cannot be followed up as scheduled;
- Patients, who in the opinion of the investigator, have any clinical or laboratory abnormalities or compliance problems and are not suitable to participate in this clinical study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rrAML
|
Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DLT
Time Frame: 28 days
|
Dose-Limiting Toxicity
|
28 days
|
MTD
Time Frame: 28 days
|
Maximal Tolerable Dose
|
28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
March 1, 2023
Primary Completion (Anticipated)
April 1, 2024
Study Completion (Anticipated)
September 1, 2024
Study Registration Dates
First Submitted
January 30, 2023
First Submitted That Met QC Criteria
February 17, 2023
First Posted (Actual)
February 21, 2023
Study Record Updates
Last Update Posted (Actual)
March 3, 2023
Last Update Submitted That Met QC Criteria
March 1, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on AML
-
H Scott BoswellTakedaTerminatedAML | AML, AdultUnited States
-
Technische Universität DresdenAbbVieActive, not recruitingRelapsed Adult AML | Refractory AMLGermany
-
Carbiogene Therapeutics Co. Ltd.Zhejiang Provincial People's HospitalRecruiting
-
National Research Center for Hematology, RussiaFederal Research Clinical Center of Federal Medical & Biological Agency,... and other collaboratorsRecruiting
-
Glycostem Therapeutics BVRecruiting
-
Etan OrgelAstellas Pharma Global Development, Inc.No longer available
-
Chinese PLA General HospitalNavy General Hospital, BeijingCompleted
-
University Hospital Inselspital, BerneWithdrawn
-
Turkish Leukemia Study GroupCompleted
Clinical Trials on NKG2D CAR-NK
-
Chongqing Public Health Medical CenterZhejiang Qixin Biotech; Chongqing Sidemu BiotechUnknown
-
Hangzhou Cheetah Cell Therapeutics Co., LtdRecruiting
-
Zhejiang UniversityRecruitingRefractory Metastatic Colorectal CancerChina
-
The Third Affiliated Hospital of Guangzhou Medical...Unknown
-
Zhejiang UniversityYake Biotechnology Ltd.Not yet recruitingAcute Myeloid LeukemiaChina
-
The Third Affiliated Hospital of Guangzhou Medical...Hangzhou Cheetah Cell Therapeutics Co., LtdRecruitingRefractory Metastatic Colorectal CancerChina
-
Fudan UniversityKAEDIRecruitingGlioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon CancerChina
-
Antonio Pérez MartínezRecruiting
-
Celyad Oncology SAUnknownAcute Myeloid Leukemia/Myelodysplastic Syndrome | Multiple Myeloma (MM)United States, Belgium
-
Jiujiang University Affiliated HospitalKAEDIWithdrawnGlioblastoma | Hepatocellular Carcinoma | Medulloblastoma | Colon CancerChina